Duke University: Central Nervous System Neoplasms trials
The registry lists 30 Central Nervous System Neoplasms studies with Duke University as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 1 17Phase 2 16No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant GliomaCompletedNCT00387933Phase 1
- Imatinib Mesylate and Temozolomide in Treating Patients With Malignant GliomaCompletedNCT00354068Phase 1
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant GliomaCompletedNCT00352521Phase 2
- Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory GliomasCompletedNCT00268359Phase 2
- Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma MultiformeWithdrawnNCT00046878Phase 2
- ZD 1839 in Treating Patients With Glioblastoma Multiforme in First RelapseCompletedNCT00016991Phase 2
- Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic GliomaCompletedNCT00006474Phase 1
- Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain TumorCompletedNCT00006342
- Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS TumorsCompletedNCT00005955Phase 2
- Temozolomide in Treating Patients With Brain MetastasesCompletedNCT00005954Phase 2
- Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid TumorsCompletedNCT00005952Phase 1/2
- Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant GliomaCompletedNCT00005951Phase 1
- Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive GliomaCompletedNCT00005081Phase 2
- Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain TumorsCompletedNCT00003478Phase 1/2
- Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade GliomaCompletedNCT00003467Phase 2
- Temozolomide in Treating Patients With Progressive Low-Grade GliomaCompletedNCT00003466Phase 2
- Temozolomide in Treating Patients With Anaplastic OligodendrogliomaCompletedNCT00003465Phase 2
- Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma MultiformeCompletedNCT00003464Phase 2
- Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade GliomasCompletedNCT00003463Phase 1
- Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal TumorsCompletedNCT00003462Phase 1
- Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain TumorsCompletedNCT00003461Phase 1/2
- Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the BrainCompletedNCT00003348Phase 1
- LMB-7 Immunotoxin in Treating Patients With Leptomeningeal MetastasesCompletedNCT00003020Phase 1
- Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant GliomaCompletedNCT00002988Phase 1
- Chemotherapy in Treating Patients With Recurrent Malignant GliomaCompletedNCT00002986Phase 1
- Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain TumorsCompletedNCT00002754Phase 1
- Monoclonal Antibody Therapy in Treating Patients With Recurrent GliomasCompletedNCT00002753Phase 1
- Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain CancersCompletedNCT00002752Phase 1/2
- Melphalan in Patients With Neoplastic MeningitisCompletedNCT00002750Phase 1
- Carboplatin in Patients With Progressive GliomasCompletedNCT00002749Phase 2